Mallinckrodt — Merger or Acquisition (December 2018)
15 slides from Mallinckrodt's merger presentation, Dec 6, 2018
Slide 1: Planned Spin-Off of Specialty Generics Business
Exhibit 99.2 Planned Spin-Off December 6, 2018of Specialty Generics Business
Slide 2: Forward-looking Statements
Forward-looking Statements and/or looking” to These spin-off, General The Conditions Changes Customer Mallinckrodt’s Cost differ proposed commercial containment factors regulatory economic materially the in statements concentration; in that laws expected include this spin-off and ability reliance co
Slide 3: Forward-looking Statements (continued)
Forward-looking Pricing Limited Future Mallinckrodt’s Complex Product Competition; Ongoing Material Retention Conducting The Cybersecurity These statements developments reimbursement effectiveness and changes pressure liability clinical health, governmental reporting manufacturing of other made busi
Slide 4: Planned Spin-off Overview
Planned Spin-off Specialty Anticipated Transaction Timing 4Key Steps Closing Expected spin-off company Generics Tothat Overview Structure Conditions Completion ittransaction towill Company pharmaceutical beExpected Separation assume completed Final Develop summary expected Board the to will in be Ma
Slide 5: Strategic rationale for the proposed separation
Strategicrespective Anticipated Creates Reflects Allows Enables 5Providestwo distinct, two investors rationale second independent, distinct focused management for with half markets a separate proposed 2019 investment publicly and orteams sooner businesses separation business traded strategies to com
Slide 6: Specialty Pharmaceutical Brands and Specialty Generics portfolio
Specialty 14% Spec Gel1 86% 2LTM Net CEO 26 6P 10 Expected 1StrataGraft®7 as-reported ortfolio BioVectra $862mm H.P. Product Dosage Sales Acthar® 23% Gx Matt Q3 Acthar INOmax®1 2018 150+ profiles H.P. Generics Breakdown Harbaugh Forms $2,311mm Families basis, &Gel Acthar and Other SKUs3 including of
Slide 7: Overview: Specialty Pharmaceutical Brands
Overview: Specialty (Assumes U.S.-based Integrated severe Focused products Pipeline 1company’s Research and selection R&D1 and Generics “Mallinckrodt” supply Two critical specialty and product Development new investment of process conditions Specialty products companies generics innovative enhanceme
Slide 8: Overview of Specialty Generics
Overview of Specialty Generics
Slide 9: Overview: Key Attributes of Specialty Generics Business
Overview Key Vertically Robust Other Expanding opportunities Enhanced Portfolio Industry-leading 1Sophisticated Last Attributes twelve R&D, Development integrated financial ofpipeline Specialty to months product manufacturing, LTM expand capabilities complex profile of Q3 specialty ended characteriz
Slide 10: Specialty Generics business summary
Specialtymanufacturer Vertically Leading Industry-leading Expanding Enhanced 10 Generics integrated financial pipeline formulation key profile inbusiness complex ofinvestment API with capabilities acetaminophen, with generics; AMITIZA, strong summary focused R&D, a well-established and manufacturing
Slide 11: Overview of Innovation-Driven Specialty Pharmaceutical Brands
Overview of Innovation-Driven Specialty Pharmaceutical Brands
Slide 12: Overview: Key Attributes of Specialty Pharmaceutical Brands
Overview Key Well-established Autoimmune Other Experienced Mid- Highly Defined 1Emphasis Last Attributes and twelve engaged business late-stage on of management the rapid and months LTM R&D innovation-driven commercial development rare execution pipeline Q3ended disease-focused organization 2018 tea
Slide 13: Specialty Pharmaceutical Brands pipeline
4321Product Specialty UVADEX® inhalation STRATAGRAFT MNK-6106 EXPRESSGRAFT (VEGF8) Planning Indication Chronic Niemann-Pick Encephalopathy Next Details Diseases/therapeutics Critical Immunologic Graft Hepatorenal Deep FullGeneration Thickness vs Partial Care Preclinical GVHD IBrands TERLIPRESSIN Hos
Slide 14: Strategic Priorities
Focused Innovation-driven Strategic Maximize Invest Execute Strengthen Portfolio Pipeline Capital Execution 14 inAllocation BD&L on the vision: Priorities: Development the the increasing current value balance to specialty enhance of pipeline stakeholder current sheet Brand the pharmaceutical and toP
Slide 15: Thank you
Thank you the “M” brand mark, the Mallinckrodt Pharmaceuticals logo and other brands 15 are trademarks of a Mallinckrodt company. © 2018 Mallinckrodt. Mallinckrodt,